STRC

Sarcos Technology and Robotics Corporation to Acquire RE2, an Award-Winning Developer of Intelligent Mobile Manipulation Systems

Retrieved on: 
Monday, March 28, 2022
Mobile, Wireless, Technology, Hardware, Adoption, Company, Private Securities Litigation Reform Act, Risk, Organization, LLP, Robotics, NASDAQ, Mission statement, Partnership, Contract, Blank Rome, Forward-looking statement, STRC, Autonomous robot, Instinct, Judgement, Research, SEC, PJT Partners, CEO, Failure, U.S. Securities and Exchange Commission, Intelligence, Professional corporation, Hand, NREC, Ernst & Young, Government, Safety, Acquisition, RE2, Machine learning, COVID-19, Intellect, Wilson Sonsini Goodrich & Rosati, P.C, Solution, Aviation, GT, Maintenance, Efficiency, AI, Technology, Security (finance), 3D printing, Risk management, Management, Stifel, Sarcos, THE TRANSACTION, SARCOS TECHNOLOGY AND ROBOTICS CORPORATION, RE2, INC.

This transaction brings together two leading commercial robotics teams focused on industrial robotic technologies that improve worker safety and productivity.

Key Points: 
  • This transaction brings together two leading commercial robotics teams focused on industrial robotic technologies that improve worker safety and productivity.
  • RE2s proven track record serving government and commercial customers makes it an ideal addition to the Sarcos team.
  • We are delighted to welcome the RE2 team to Sarcos, said Kiva Allgood, President and CEO, Sarcos.
  • Wilson Sonsini Goodrich & Rosati, Professional Corporation is acting as legal counsel and PJT Partners is acting as financial advisor to Sarcos.

Sarcos Technology and Robotics Corporation Announces Webcast of Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Tuesday, March 15, 2022
SEC, Intelligence, GLOBE, GT, Private Securities Litigation Reform Act, Form, Forward-looking statement, Judgement, Safety, Security (finance), NASDAQ, SALT, Research, Robotics, U.S. Securities and Exchange Commission, Sarcos, Instinct, STRC, Technology

SALT LAKE CITY, March 15, 2022 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (Sarcos) (NASDAQ: STRC and STRCW) will webcast a live audio feed of its fourth quarter and full year 2021 financial results conference call with financial analysts on Tuesday, March 29, 2022, at 5.00 p.m.

Key Points: 
  • SALT LAKE CITY, March 15, 2022 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (Sarcos) (NASDAQ: STRC and STRCW) will webcast a live audio feed of its fourth quarter and full year 2021 financial results conference call with financial analysts on Tuesday, March 29, 2022, at 5.00 p.m.
  • An archive of the call will be available beginning on March 29, 2022, at investor.sarcos.com through April 29, 2022.
  • These forward-looking statements are based on Sarcos managements current expectations and beliefs, as well as a number of assumptions concerning future events.
  • The documents filed by Sarcos with the SEC may be obtained free of charge at the SECs website at www.sec.gov.

Sarcos Technology and Robotics Corporation Meets Development Milestone for its Guardian® XT™ Robotic Avatar System

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, CEO, Sarcos, Alpha, Beta, Intelligence, Forward-looking statement, STRC, Wrist, SEC, GT, Technology, Research, Private Securities Litigation Reform Act, NASDAQ, Robotics, Security (finance), Company, Freedom, Instinct, XT, Judgement, GLOBE, SALT, Safety, Mobile phone, 3D printing, Guardian

The Guardian XT robot is an upper-body variant of the award-winning Sarcos Guardian XO full-body, battery-powered industrial exoskeleton .

Key Points: 
  • The Guardian XT robot is an upper-body variant of the award-winning Sarcos Guardian XO full-body, battery-powered industrial exoskeleton .
  • Sarcos is currently conducting internal Beta testing of the Guardian XT robotic avatar system and expects to deliver units to partners for additional testing in mid-2022.
  • We are extremely pleased with the progress weve made in the development of our Guardian XT robotic system, said Kiva Allgood, president and CEO, Sarcos.
  • Leveraging more than 30 years of research and development, Sarcos mobile robotic systems, including the Guardian S, Guardian GT, Guardian XO, and Guardian XT, are designed to revolutionize the future of work wherever physically demanding work is done.

Sarcos Technology and Robotics Corporation to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, January 4, 2022
Research, Sarcos, Robotics, Judgement, Safety, NASDAQ, Intelligence, STRC, Instinct, GT, Technology, Auction, 3D printing, Heavy equipment

For more information on Sarcos and its award-winning product portfolio, please visit www.sarcos.com .

Key Points: 
  • For more information on Sarcos and its award-winning product portfolio, please visit www.sarcos.com .
  • Sarcos Technology and Robotics Corporation (NASDAQ: STRC and STRCW) is a leader in industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity.
  • Leveraging more than 30 years of research and development, Sarcos mobile robotic systems, including the Guardian S, Guardian GT, Guardian XO, and Guardian XT, are designed to revolutionize the future of work wherever physically demanding work is done.
  • Sarcos is based in Salt Lake City, Utah.

Sarcos Technology and Robotics Corporation Strengthens Leadership Team by Appointing Ben Wolff Executive Chairman and Technology Veteran Kiva Allgood as New Chief Executive Officer

Retrieved on: 
Monday, December 13, 2021
GT, Forward-looking statement, U.S. Securities and Exchange Commission, Kiva, New business development, General Electric Company, Ben, Intelligence, Technology, Robotics, IOT, Private Securities Litigation Reform Act, Innovation, GE Ventures, Instinct, NASDAQ, SEC, Automotive industry, Qualcomm, CEO, Research, Safety, Sarcos, Security (finance), Leadership, Ericsson, SALT, GLOBE, Allgood, STRC, Human, Judgement, Management

SALT LAKE CITY, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC and STRCW), a leader in the development of robotic systems that augment humans to enhance productivity and safety, today announced Ben Wolff, current chairman and chief executive officer, has been named executive chairman and will pass the roles of president and chief executive officer to Kiva Allgood, an experienced technology executive with public company experience leading global business units effective immediately.

Key Points: 
  • Our incredible team has accomplished a great deal in the six-plus years that I have served as CEO, said Wolff.
  • Allgood most recently served as Global Head of IoT and Automotive for Ericsson, a global provider of communications technology.
  • I am honored to be chosen by Ben and the rest of the distinguished board to lead Sarcos, said Allgood.
  • Sarcos future under the leadership of Ben and Kiva is very bright, said Dennis Weibling, Sarcos lead director.

Decibel Therapeutics Announces Extension of Research Term under Strategic Collaboration with Regeneron to Discover and Develop Gene Therapies for Hearing Loss

Retrieved on: 
Monday, November 22, 2021
Patient, Security (finance), Private Securities Litigation Reform Act, Company, Hearing, Gene, GJB2, SEC, U.S. Securities and Exchange Commission, COVID-19, Twitter, Research, Entrepreneurship, Mutation, Investor, GLOBE, Terminology, Regeneron Pharmaceuticals, Medicine, STRC, Therapy, Hearing loss, Pharmaceutical industry

The research term will be extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.

Key Points: 
  • The research term will be extended to November 15, 2023, and Regeneron will pay Decibel an extension fee of $10 million in Q4 of 2022.
  • Under the collaboration launched in 2017, Decibel is developing three gene therapy programs targeting congenital, monogenic hearing loss with Regeneron.
  • Decibel is also advancing AAV.103 and AAV.104, gene therapy programs targeting other monogenic forms of hearing loss, with Regeneron.
  • AAV.103 aims to restore hearing in individuals with mutations in the GJB2 gene, and AAV.104 aims to restore hearing in individuals with mutations in the STRC gene.

Sarcos Technology and Robotics Corporation to Participate in Upcoming Investor Conference

Retrieved on: 
Monday, November 22, 2021
Sarcos, GT, Robotics, Technology, Judgement, Research, STRC, Instinct, Safety, NASDAQ, Intelligence, Auction, 3D printing, Heavy equipment

For more information on Sarcos and its award-winning product portfolio, please visit www.sarcos.com .

Key Points: 
  • For more information on Sarcos and its award-winning product portfolio, please visit www.sarcos.com .
  • Sarcos Technology and Robotics Corporation (NASDAQ: STRC and STRCW) is a leader in industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity.
  • Leveraging more than 30 years of research and development, Sarcos mobile robotic systems, including the Guardian S, Guardian GT, Guardian XO, and Guardian XT, are designed to revolutionize the future of work wherever physically demanding work is done.
  • Sarcos is based in Salt Lake City, Utah.

Sarcos Technology and Robotics Corporation Moves into New Headquarters and Production Facility in Salt Lake City

Retrieved on: 
Thursday, November 18, 2021
Sarcos, Private Securities Litigation Reform Act, Judgement, Security (finance), CEO, Safety, Forward-looking statement, SALT, Human, SEC, U.S. Securities and Exchange Commission, Robotics, Technology, Research, GLOBE, CBRE, GT, STRC, Instinct, NASDAQ, Intelligence, 3D printing, Risk management

SALT LAKE CITY, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (Sarcos) (NASDAQ: STRC and STRCW), a leader in the development of robotic systems that augment humans to enhance productivity and safety, today announced that it has moved into a new headquarters and production facility in the Granary District of Salt Lake City.

Key Points: 
  • SALT LAKE CITY, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sarcos Technology and Robotics Corporation (Sarcos) (NASDAQ: STRC and STRCW), a leader in the development of robotic systems that augment humans to enhance productivity and safety, today announced that it has moved into a new headquarters and production facility in the Granary District of Salt Lake City.
  • We are thrilled to be in our new, state-of-the-art headquarters, said Ben Wolff, Chairman and CEO, Sarcos.
  • The new Sarcos headquarters is located at 650 S 500 W. Suite 150, Salt Lake City, UT, 84101, within the INDUSTRY Salt Lake City building.
  • The documents filed by Sarcos with the SEC may be obtained free of charge at the SECs website at www.sec.gov.

Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
CTA, Therapy, Birth defect, Security (finance), Terminology, Gene, Food, COVID-19, Treatment, Tinnitus, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hearing, Regeneration, STRC, Cell, Prevalence, Karolinska Institute, USPTO, Cisplatin, Regeneron Pharmaceuticals, Congenital hearing loss, GJB2, Cell Reports, BVP, Research, University of Maryland School of Medicine, GLOBE, U.S. Securities and Exchange Commission, Noise-induced hearing loss, Cochlea, Program, United States Patent and Trademark Office, Patent, FDA, Bilateral vestibulopathy, Private Securities Litigation Reform Act, State Administrative Expenses, Medicine, Sale, Twitter, SEC, University, Ear, Maryland School, Hearing loss, Administration, Development, Company, IND, Pharmaceutical industry, Dentistry

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Third Quarter 2021 Financial Results:
    Cash Position: As of September 30, 2021, cash, cash equivalents and available-for-sale securities were $172.4 million.
  • Research and Development Expenses: Research and development expenses were $9.0 million for the third quarter of 2021, compared to $4.7 million for the third quarter of 2020.
  • However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Sarcos Technology and Robotics Corporation to Participate in Upcoming November Investor Conferences

Retrieved on: 
Wednesday, October 27, 2021
Safety, Judgement, Research, Bank, Instinct, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NASDAQ, SEC, Intelligence, Technology, Conference, Forward-looking statement, STRC, GT, Form, Sarcos, Robotics

For more information on Sarcos, its leadership team, and its award-winning product portfolio, please visit www.sarcos.com .

Key Points: 
  • For more information on Sarcos, its leadership team, and its award-winning product portfolio, please visit www.sarcos.com .
  • Sarcos Technology and Robotics Corporation (NASDAQ: STRC and STRCW) is a leader in industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity.
  • These forward-looking statements are based on Sarcos managements current expectations and beliefs, as well as a number of assumptions concerning future events.
  • The documents filed by Sarcos with the SEC may be obtained free of charge at the SECs website at www.sec.gov.